Drugs / GSK2849466
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01696604 | Sep 2012 → May 2013 | hypoproteinemia, hypercatabolic | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2849466 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01696604 ↗ |
| Modality | Other / unclassified | “Selective Androgen Receptor Modulator (SARM)” NCT01696604 ↗ |
| Route | Oral | “given as single and repeat oral doses up to 14 days” NCT01696604 ↗ |
| Target | AR | “Androgen Receptor modulator” CHEMBL3545046 ↗ |